新辅助治疗影响早期非小细胞肺癌的肿瘤生长标志物。

Neoadjuvant therapy affects tumor growth markers in early stage non-small-cell lung cancer.

机构信息

Laboratory of Molecular Diagnostics and Immunology, National Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.

出版信息

Eur J Med Res. 2009 Dec 7;14 Suppl 4(Suppl 4):42-4. doi: 10.1186/2047-783x-14-s4-42.

DOI:10.1186/2047-783x-14-s4-42

PMID:20156723

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3521347/

Abstract

INTRODUCTION

While adjuvant therapy of early-stage non-small-cell lung cancer (NSCLC) is widely accepted, literature data concerning neoadjuvant treatment provide contradictory results with both improved and unaffected survival rates. Also, data concerning potential effects of neo-adjuvant therapy on cellular level are scarce.

OBJECTIVE

The aim of present study was to analyze the effect of chemotherapy followed by surgical resection on several key biological markers of tumor growth (TGF-beta, VEGF), apoptosis (sAPO-1/Fas/CD95) and invasiveness (TIMP-1) assessed in the sera of NSCLC early-stage patients (IB-IIIA). -

MATERIAL AND METHODS

Measurements were performed by ELISA method in blood serum from 24 NSCLC patients (I-IIIA) collected prior therapy, one day before surgery and 3 days after.

RESULTS

TGF-beta serum concentrations were significantly lower after both chemotherapy (P<0.05) and surgery (P<0.01) in comparison to the baseline. VEGF levels decreased following NEO therapy with subsequent significant up-regulation after surgery (P<0.001). Interestingly, post-surgery serum VEGF strongly correlated with TGF-beta concentration (r = 0.52, P = 0.014). No significant differences were observed for serum sAPO-1/CD95/FAS as well as TIMP-1 concentrations at any of three evaluated time-points.

CONCLUSION

Neoadjuvant treatment of early-stage NSCLC affects mostly mechanisms responsible for tumor growth and vascularization. Its effect on cancer cells apoptotic activity needs further evaluation.

摘要

简介

虽然辅助治疗早期非小细胞肺癌（NSCLC）已被广泛接受，但有关新辅助治疗的文献数据提供了相互矛盾的结果，既有改善的生存率，也有未受影响的生存率。此外，关于新辅助治疗对细胞水平潜在影响的数据也很少。

目的

本研究旨在分析化疗后手术切除对早期非小细胞肺癌（IB-IIIA）患者血清中几种肿瘤生长关键生物学标志物（TGF-β、VEGF）、凋亡（sAPO-1/Fas/CD95）和侵袭性（TIMP-1）的影响。

材料和方法

通过 ELISA 法在 24 名 NSCLC 患者（I-IIIA）的血清中进行测量，这些患者在治疗前、手术前一天和手术后 3 天采集血液。

结果

与基线相比，化疗（P<0.05）和手术（P<0.01）后血清 TGF-β浓度均显著降低。NEO 治疗后 VEGF 水平下降，随后手术后显著上调（P<0.001）。有趣的是，手术后血清 VEGF 与 TGF-β浓度强烈相关（r = 0.52，P = 0.014）。在三个评估时间点中的任何一个时间点，血清 sAPO-1/CD95/FAS 以及 TIMP-1 浓度均无显著差异。